Mounjaro Before and After 1 Month: What Really Happens in Week One to Four

What the trial evidence actually shows about early weight loss on Mounjaro

The SURMOUNT-1 trial, published in the New England Journal of Medicine, followed over 2,500 adults with obesity across 72 weeks. The trial's published weight-loss curves show that the steepest rate of loss tends to come once higher doses are reached, typically beyond the first two months. In week one to four, participants were on 2.5mg, the introductory rung of the schedule.

That starter dose exists for a specific reason. Tirzepatide slows gastric emptying and acts on two gut-hormone pathways (GIP and GLP-1) to reduce appetite and improve blood-sugar regulation. Introducing it gradually gives the digestive system time to adapt. So if you're reading before-and-after accounts from people at the one-month mark and wondering why the numbers are more modest than the headline figures, this is why. One month is closer to the beginning than the middle.

What the data do show at four weeks is real biological change. Appetite suppression begins early. Many participants in SURMOUNT-1 reported eating less without consciously trying to restrict. Blood sugar begins to respond. The NHS medicines page for tirzepatide confirms this mechanism and outlines what patients can reasonably expect as treatment progresses.

A realistic first-month figure, based on the trial trajectory, is roughly 1–4% of starting body weight. For someone starting at 100kg, that is 1–4kg in four weeks, not dramatic on paper, but a genuine signal that treatment is working.

Physical changes people notice before the scales move much

Weight on a scale is not the only thing shifting in month one. People who document their Mounjaro journey often describe changes that don't show up as a number on the bathroom floor.

Hunger patterns shift first. The urge to snack between meals often fades, and the amount needed to feel full at a meal tends to fall. This is the medicine doing its job, not a placebo effect, but a measurable change in gut-hormone signalling that the trial data support.

Some people also notice changes in facial fullness within the first month. This varies considerably between individuals, genetics, water retention, starting weight distribution all play a role. If that's a specific area you're curious about, our page on facial changes at one month looks at that in more detail.

Energy levels can go either way early on. Some people feel lighter and less sluggish fairly quickly; others find the adjustment period tiring, particularly if GI symptoms are disrupting sleep or meals. Both are within the normal range at four weeks. What most people report, looking back, is that month one was the hardest and that it got progressively easier.

Clothing fit can also shift before the scales reflect it. Fat loss and fluid changes can alter body composition in ways that centimetres catch before kilograms do. Keeping a measurement log alongside weekly weigh-ins gives a more complete picture of what month one is actually doing.

Side effects in the first four weeks and how to manage them

The most common experiences in week one to four are gastrointestinal. Nausea tops the list. Then come constipation, loose stools, burping and reflux, in varying combinations and intensities. For most people these are mild, front-loaded and improving by week three or four.

They're also the reason the starter dose is 2.5mg. Starting low and titrating slowly under prescriber guidance is the mechanism that keeps side effects manageable. Going straight to a higher dose would likely make the first month considerably harder.

There are symptoms that warrant prompt medical attention and shouldn't be attributed to normal adjustment. Severe stomach pain (especially pain that radiates towards the back) needs same-day medical assessment to rule out pancreatitis. The MHRA flagged acute pancreatitis as a known but infrequent risk in its Yellow Card reporting system and associated Drug Safety Update in January 2026. Signs of dehydration from persistent vomiting or diarrhoea also require prompt attention.

Most people find that eating smaller portions, avoiding very fatty or rich meals, and staying well hydrated makes the first month considerably easier. These are practical habits that also support the weight-loss process itself, so they compound over time.

What month one predicts (and what it doesn't) about your longer results

A modest first month does not predict a modest outcome. The trajectory of weight loss on Mounjaro is not linear, and the evidence consistently shows that results build as the dose increases and time accumulates. If you want a more detailed sense of how progress tends to develop, our pages covering eight week weight loss results at the one-month stage and before and after results at two months show how the picture shifts as treatment continues. The full picture of before-and-after results at longer intervals (three months and beyond) looks very different from the four-week snapshot.

The question our prescribers hear most often in the early weeks is some version of: is this working? The honest answer is that at 2.5mg for four weeks, it's too early to judge efficacy. The clinical benchmark used in the SURMOUNT-1 protocol and referenced in NICE's appraisal of tirzepatide (TA1026) is weight loss at six months on the highest tolerated dose, not at four weeks on the starter dose.

Timing matters in an everyday sense too. People who order and start mid-month, around payday, or before a holiday often find their first four weeks are interrupted by social eating or travel. That's normal, and it doesn't derail the process. What matters is consistency over months, not perfection over weeks.

If you're weighing up cost alongside effectiveness, our overview of Mounjaro pricing in the UK sets out the current landscape honestly. And if you want to understand the longer arc of what Mounjaro can achieve, the full before-and-after evidence page covers the complete trial picture.

Mounjaro is a prescription-only medicine. Starting treatment through a regulated, clinically led service means a real prescriber reviews your health picture before anything is dispensed. If you'd like to explore whether it's clinically suitable for you, you can start a free consultation with our GPhC-registered prescribers today.